Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion

Acta Ophthalmologica

Volumn 92, Issue 7, 2014, Pages e530-e539

  Ramezani, Alireza ^a,b   Esfandiari, Hamed ^a   Entezari, Morteza ^a   Moradian, Siamak ^a   Soheilian, Masoud ^a   Dehsarvi, Babak ^a   Yaseri, Mehdi ^a,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

central retinal vein occlusion; intravitreal bevacizumab; intravitreal triamcinolone; retinal vein occlusion

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; RETINA; RETINAL VEIN OCCLUSION; SINGLE BLIND PROCEDURE; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84927171164     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12317     Document Type: Article

References (50)

1. Algvere PV, Epstein D, von Wendt G, Seregard S, &, Kvanta A, (2011): Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 21: 789-795.
2. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, &, Rodriguez FJ, (2009): Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 247: 735-743.
3. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, &, Miller M, (2003): Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110: 681-686.
4. Bezatis A, Spital G, Hohn F, et al., (2013): Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-the SOLO study. Acta Ophthalmol 91: e340-e347.
5. Braithwaite T, Nanji AA, &, Greenberg PB, (2010): Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 10: CD007325.
6. Brown DM, Campochiaro PA, Singh RP, et al., (2010): Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1124-1133.
7. Campochiaro PA, (2012): Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica 227 (Suppl 1): 30-35.
8. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, &, Rubio RG, (2011): Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118: 2041-2049.
9. Chang LK, Spaide RF, Klancnik JM, et al., (2011): Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 31: 821-828.
10. Coscas G, Loewenstein A, Augustin A, et al., (2011): Management of retinal vein occlusion-consensus document. Ophthalmologica 226: 4-28.
11. Central Vein Occlusion Study Group CRVO (1993): Central vein occlusion study of photocoagulation. Manual of operations. Online J Curr Clin Trials Doc No 92: [32,228 words; 678 paragraphs].
12. Daien V, Navarre S, Fesler P, Vergely L, Villain M, &, Schneider C, (2012): Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 22: 1013-1018.
13. DeCroos FC, Ehlers JP, Stinnett S, &, Fekrat S, (2011): Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Curr Eye Res 36: 1164-1170.
14. Ding X, Li J, Hu X, Yu S, Pan J, &, Tang S, (2011): Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 31: 838-845.
15. Epstein DL, Algvere PV, von Wendt G, Seregard S, &, Kvanta A, (2012): Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119: 1184-1189.
16. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, &, Lai P, (2012): Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119: 802-809.
17. Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, &, Ohji M, (2013): Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol 91: 318-324.
18. Hung KH, Lee SM, Lee SY, Lee FL, &, Yang CS, (2010): Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther 26: 85-90.
19. Ip MS, Scott IU, VanVeldhuisen PC, et al., (2009): A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127: 1101-1114.
20. Jonas JB, (2005): Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 83: 645-663.
21. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, &, Degenring RF, (2005): Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15: 751-758.
22. Joshi L, Tomkins-Netzer O, Menezo V, Sallam A, Kirkpatrick N, Lightman S, &, Taylor SR, (2013): Dexamethasone implants and neovascular glaucoma in central retinal vein occlusion. Acta Ophthalmol 91: e239-e240.
23. Kim H, Csaky KG, Gravlin L, et al., (2006): Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 26: 523-530.
24. Kim M, Yu SY, Kim ES, Bae SH, Park JH, Yu HG, &, Kwak HW, (2012): Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion. Ophthalmologica 227: 132-138.
25. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, &, Stene-Johansen I, (2010): Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 150: 310-314.
26. Krohne TU, Eter N, Holz FG, &, Meyer CH, (2008): Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146: 508-512.
27. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, &, Bandello F, (2011): Retinal vein occlusion: current treatment. Ophthalmologica 225: 135-143.
28. Lazic R, Boras I, Vlasic M, Gabric N, &, Tomic Z, (2010): Anti-VEGF in treatment of central retinal vein occlusion. Coll Antropol 34 (Suppl 2): 69-72.
29. London NJ, &, Brown G, (2011): Update and review of central retinal vein occlusion. Curr Opin Ophthalmol 22: 159-165.
30. Manousaridis K, &, Talks J, (2012): Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? Br J Ophthalmol 96: 179-184.
31. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, &, Baumal C, (2002): Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109: 920-927.
32. Matonti F, Meyer F, Guigou S, et al., (2013): Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 91: e584-586.
33. McAllister IL, (2012): Central retinal vein occlusion: a review. Clin Experiment Ophthalmol 40: 48-58.
34. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, &, Ohji M, (2010): Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 51: 1606-1608.
35. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, &, Roth M, (1998): Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341: 309-315.
36. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, &, Keshet E, (1998): Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105: 412-416.
37. Pieramici DJ, &, Rabena MD, (2008): Anti-VEGF therapy: comparison of current and future agents. Eye (Lond) 22: 1330-1336.
38. Ramezani A, Entezari M, Moradian S, Tabatabaei H, &, Kadkhodaei S, (2006): Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 244: 1601-1606.
39. Ramezani A, Esfandiari H, Entezari M, Moradian S, Soheilian M, Dehsarvi B, &, Yaseri M, (2012): Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 250: 1149-1160.
40. Rogers SL, McIntosh RL, Lim L, et al., (2010): Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117: 1094-1101.
41. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, &, Chaudhry NA, (2003): Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121: 1279-1282.
42. Shah NJ, &, Shah UN, (2011): Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study. Eye (Lond) 25: 239-244.
43. Sutter FK, &, Gillies MC, (2003): Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 87: 972-974.
44. Tao Y, Hou J, Jiang YR, Li XX, &, Jonas JB, (2010): Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 24: 810-815.
45. Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S, &, Rubio RG, (2012): Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119: 2108-2118.
46. Wang HY, Li X, Wang YS, Zhang ZF, Li MH, Su XN, &, Zhu JT, (2011): Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. Int J Ophthalmol 4: 89-94.
47. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, &, de Juan E jr, (1992): Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 110: 1155-1159.
48. Wu L, Arevalo JF, Roca JA, et al., (2008): Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 28: 212-219.
49. Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Canton V, Alezzandrini AA, &, Diaz-Llopis MJ, (2010): Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Retina 30: 1002-1011.
50. Zhang H, Liu ZL, Sun P, &, Gu F, (2011): Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 27: 615-621.